Strategic partnerships WhiteLab Genomics has active collaborations with Debiopharm, Siren Biotechnology, and Sanofi, indicating a strong in-market validation and a ready-made venue for co-development discussions, licensing opportunities, and joint R&D campaigns.

AI driven platforms Their proprietary AI platform for design and optimization of delivery systems across viral and non-viral vectors, RNA and DNA payloads suggests upsell potential in computational biology services, optimized pipelines, and platform-enabled reverse translation for client programs.

Therapeutic focus Focused work spans oncology, neurology, ophthalmology, auditory disorders, and rare diseases, enabling tailored outreach to biotech and pharma teams pursuing gene therapies, CNS targets, or rare-disease programs seeking safer, more effective delivery solutions.

Global footprint Presence in Paris, Boston, and Montréal positions the company for cross‑regional collaboration and access to North American and European biotech ecosystems, ideal for multi-region studies, clinical preparations, and partner-sponsored research.

Industry momentum Recent announcements include partnerships with Debiopharm and Siren Biotechnology, upcoming ASGCT 2025 participation, and a background of YC and French Tech 2030 backing, signaling growing credibility and opportunities for milestone-based deals and strategic investments.